A Growth Factor Slows Spinal Disc Aging — in Rats
Back pain from worn-down spinal discs is one of the most common complaints in aging adults.
The intervertebral discs — the cushions between your vertebrae — are among the first tissues to show signs of aging. As they degenerate, they shrink, stiffen, and lose their ability to absorb pressure. The result is chronic lower back pain, a near-universal experience for older adults and a growing public health burden. Existing treatments manage symptoms. None address the underlying biology of disc aging.
Researchers publishing in Aging Cell took a molecular approach. They focused on FGF21 — fibroblast growth factor 21 — a protein typically studied in the context of fat metabolism and insulin sensitivity. Their key finding: FGF21 can activate SIRT1, a member of the sirtuin family. Sirtuins are enzymes long associated with aging regulation; SIRT1 specifically helps protect cells from stress and suppresses inflammation.
Less damage, better structure
In rat experiments, animals treated with FGF21 showed markedly less disc degeneration over time. Their discs retained better structural integrity, and there was a reduced accumulation of senescent cells — damaged cells that stop dividing but release inflammatory signals that harm surrounding tissue. This so-called zombie-cell phenomenon is considered one of the core drivers of tissue aging across the body.
The researchers propose that FGF21, acting through SIRT1, both reduces the formation of these senescent cells and dampens the inflammatory response within disc tissue. That’s a meaningful mechanistic finding. But the gap between a rat model and a human clinical application remains wide. Human spinal biology — shaped by upright posture and decades of load-bearing — is considerably more complex. FGF21 is not currently approved as a therapeutic for disc degeneration.
Two familiar players, one new connection
What makes this study notable beyond its immediate clinical implications is how it links two well-studied aging biology pathways. SIRT1 has been a focal point of longevity research since studies connected caloric restriction with extended lifespan in model organisms. FGF21 has been explored primarily in metabolic disease — obesity and diabetes. Their joint role in tissue-specific aging of the spine adds a new dimension to both research lines.
Whether this eventually produces a treatment for people with degenerative disc disease depends on a long road of further research: first confirming the mechanism works in human cells, then navigating clinical trials that take years. What the study does confirm is that spinal discs are not simply passive, wear-prone structures. They are biologically active tissue that responds to molecular signals — and that remains one of the more useful insights aging research keeps delivering.